RDIF announces start of obtaining permission to use Sputnik V in EU


The first stage of obtaining permission for the use of the Russian Satellite V coronavirus vaccine in the European Union is scheduled for January 19, said Kirill Dmitriev, general director of the Russian Direct Investment Fund (RDIF). We are talking about the so-called scientific review. The application for permission for emergency use (EUA, emergency use authorization) of the RDIF Sputnik V vaccine was filed on December 22.

The process of registering a Russian vaccine with the European Medicines Agency (EMA) was launched at the end of October. At the moment, EMA has registered two vaccines – co-produced by Pfizer and BioNTech, as well as Moderna.

The head of the RDIF said that registration in another 10 states is expected in the near future. Now the vaccine is produced in Korea and India, on January 15 production will begin in Brazil, it is planned to begin production in China.

Dmitriev said that “throughout the world, except for a number of Western countries, the attitude to the Russian vaccine is positive, and Russian medicine is recognized as one of the world leaders.”